Cardiol Therapeutics Inc. (CRDL)
NasdaqCM · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$1.12 (+0.00%) as of
Key statistics
- Market cap
- 136.09M
- Forward P/E
- -4.81
- EPS (TTM)
- -0.2500
- Dividend yield
- 0.00%
- 52-week range
- 0.8800 – 2.3400
- Beta
- 0.73
- Profit margin
- 0.00%
- Analyst target
- $8.58
- Volume
- 579.48k
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Oakville, ON, Canada
- Employees
- 18
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.